health
Chinese drug VV116 shows effectiveness against Nipah virus
Researchers at the Wuhan Institute of Virology have taken a crucial step in the fight against the Nipah virus, a deadly pathogen that has health authorities on high alert, especially in regions like India. According to a media report South China Morning Post (SCMP), the Chinese drug VV116, initially created to combat the Covid-19 pandemic, has proven effective in slowing the action of this virus, which to date lacks a definitive cure or vaccine.
TL;DR
- The COVID-19 antiviral drug VV116 has shown effectiveness against the Nipah virus.
- Oral administration of VV116 increased survival rates in golden hamsters by up to 66.7%.
- The drug reduced the presence of the Nipah virus in the brain, spleen, and lungs.
- VV116 is presented in tablet form, offering logistical advantages for distribution.
- It can be used as a preventative drug for high-risk groups and a treatment option for outbreaks.
- Nipah virus is classified as a top priority threat by the WHO with a high mortality rate (40%-75%).
- Current treatments for Nipah virus are lacking, with no specific therapies or vaccines available.
- Symptoms can mimic other respiratory illnesses but can progress to encephalitis (brain inflammation).